RANDOMIZED TRIAL OF UROPHOS-K IN ABSORPTIVE HYPERCALCIURIA

UROPHOS-K 治疗吸收性高钙尿症的随机试验

• 批准号: 6567677
• 负责人: CHARLES Y.C PAK
• 金额: $ 32.14万
• 依托单位: UT SOUTHWESTERN MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-12-01 至 2002-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6567677
• 关键词: chemotherapy; citrates; clinical research; clinical trials; drug screening /evaluation; human subject; human therapy evaluation; hypercalciuria; nephrolithiasis; nutrition related tag; phosphates; potassium; slow release drug; urinalysis

The overall aim of this project is to determine whether a special formulation of orthophosphate (slow-release neutral potassium phosphate or Uro-Phos-K would correct hypercalciuria, prevent recurrent stone formation and provide safety of usage in hypercalciuric nephrolithiasis. In a controlled randomized trial, the effect of Uro-Phos-K will be compared with those of Urocie-K (potassium citrate) in hypercalciuric patients with recurrent nephrolithiasis. The hypothesis to be tested is that UroPhos-K unlike Urocie-K would lower urinary calcium, and would be more effective that Urocie-K in inhibiting new stone formation.

该项目的总体目标是确定一个特殊的 正磷酸盐（缓释中性磷酸钾）制剂 或Uro-Phos-K可纠正高钙尿症，防止结石复发 并提供高尿钙肾结石的安全使用。 在一项随机对照试验中，Uro-Phos-K的作用将是 与Urocie-K（柠檬酸钾）相比， 复发性肾结石患者。 待测试的假设 与Urocie-K不同，UroPhos-K会降低尿钙， 在抑制新结石形成方面比Urocie-K更有效。